Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.72 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 4/20 | 0.68 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092594 | 0.98 | NR4A1 (0.70) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL339813 | 0.87 | LMNA (0.82) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL11098291 | 0.85 | NR4A1 (0.74) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL5386288 | 0.84 | NR4A1 (0.68) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL6830467 | 0.84 | NR4A2 (1.00) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL228477 | 0.84 | NR4A2 (1.00) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL4059143 | 0.84 | NR4A2 (1.00) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL3232949 | 0.84 | SRD5A2 (0.90) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL28516316 | 0.84 | MAOB (0.68) | NR4A1NR4A2NR4A3PTGS1PTGS2 | |
| Monobenzone SCHEMBL11272996 | 0.83 | LMNA (1.00) | NR4A1NR4A2NR4A3LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1670810-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI | Isis Pharmaceuticals, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | claimed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | claimed |
| WO-2005023825-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | claimed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1181301-A1 | OLIGONUCLEOTIDE SYNTHESIS WITH LEWIS ACIDS AS ACTIVATORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2000075157-A1 | OLIGONUCLEOTIDE SYNTHESIS WITH LEWIS ACIDS AS ACTIVATORS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | claimed |
| JP-H09510206-A | — | — | 1997-10-14 | — | — | JP | claimed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | claimed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | claimed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | NR4A1 4658/4885NR4A2 4755/4885NR4A3 4725/4885 |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | NR4A1 1889/4885NR4A2 2147/4885NR4A3 1648/4885 |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | NR4A1 1889/4885NR4A2 2147/4885NR4A3 1648/4885 |
| US-20050208588-A1 | Supports for oligomer synthesis | ILK, NOP2, PFAS | NR4A1 4658/4885NR4A2 4755/4885NR4A3 4725/4885 |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | NEFM, POLRMT, POLM | NR4A1 2383/4885NR4A2 3198/4885NR4A3 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.